Drug profile · INN
inotuzumab ozogamicin
BESPONSA
inotuzumab ozogamicin (BESPONSA) is a cd22 binding agent. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Drug details — inotuzumab ozogamicin
- US status
- approved
- Class
- Antineoplastic and immunomodulating agents (L01)
- Route
- —
- Patents
- 0
- Programs
- 7
- Data quality
- 0.83
Quick answer
inotuzumab ozogamicin (BESPONSA) is a cd22 binding agent. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
Key facts
Mechanism of action
CD22 binding agent
Primary target: B-cell receptor CD22
Approval history
| Authority | Status | Date |
|---|---|---|
| FDA | approved | — |
| EMA | approved | — |
| TGA | approved | — |
| PMDA | approved | — |
Pipeline programs
Related & competitor drugs
Frequently asked questions
What is inotuzumab ozogamicin?
inotuzumab ozogamicin (BESPONSA) is a cd22 binding agent. Associated with Pfizer Australia Pty Ltd. Current US regulatory status: approved.
What is the brand name for inotuzumab ozogamicin?
BESPONSA is a marketed brand name for inotuzumab ozogamicin. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of inotuzumab ozogamicin?
inotuzumab ozogamicin has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.